EUVIMEDEUVIMED entdecken
Fallbericht

SMARCB1‐Deficient Pulmonary Mesenchymal Tumor Without Malignant Histological Features

Nozomi Nakajima, Kohei Fukuoka, Seshiru Nakazawa, Yoichi Ohtaki iD, Nozomi Matsumura iD, Ayako Yamazaki, Hideaki Yokoo, Akihiko Yoshida, Sumihito Nobusawa iD

Pathology International · 2025

DOI: 10.1111/pin.70025 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Pathology International, 2025. Verfasst von Nozomi Nakajima und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Pathology, Gunma University Graduate School of Medicine, Maebashi, Japan. Hauptthemen laut MEDLINE: SMARCB1 Protein, Lung Neoplasms, Mesenchymoma. Die Arbeit nennt 17 Literaturangaben. Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Complete loss of nuclear SMARCB1 expression was originally described as a hallmark of malignant rhabdoid tumors, typically occurring in the kidney, soft tissue, and central nervous system (CNS). Generally, SMARCB1 deficiency is associated with malignant histopathological appearance, except for some rare tumors. Herein, we present a case of hitherto undescribed SMARCB1‐deficient pulmonary mesenchymal tumor without rhabdoid features or malignant histopathology involving a 62‐year‐old male patient. Histologically, the tumor demonstrated a moderately cellular proliferation of monomorphic spindle cells arranged in short fascicles or a storiform pattern with intervening collagenous stroma. The mitotic activity was lower than that of typical SMARCB1‐deficient tumors, and rhabdoid features and necrosis were absent. Nuclear SMARCB1 expression was lost, and a part of SMARCB1 was revealed to be homozygously deleted. DNA methylation analysis demonstrated that this case was not clustered with other well‐known SMARCB1‐deficient tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SMARCB1 ProteinLung NeoplasmsMesenchymomaHumansMaleMiddle AgedDNA MethylationBiomarkers, TumorRhabdoid Tumor

Stichwörter der Autor:innen

DNA methylationSMARCB1lungmesenchymal tumor

Substanzen

SMARCB1 ProteinSMARCB1 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Human Pathology, Gunma University Graduate School of Medicine, Maebashi, Japan.
  • Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
  • Division of General Thoracic Surgery, Integrative Center of General Surgery, Gunma University Hospital, Maebashi, Japan.
  • Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.

ORCID-Profile: Yoichi Ohtaki, Nozomi Matsumura, Sumihito Nobusawa

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Nakajima, N., Fukuoka, K., Nakazawa, S., Ohtaki, Y., Matsumura, N., Yamazaki, A., Yokoo, H., Yoshida, A., & Nobusawa, S. (2025). SMARCB1‐Deficient Pulmonary Mesenchymal Tumor Without Malignant Histological Features. Pathology International. https://doi.org/10.1111/pin.70025

Vancouver

Nakajima N, Fukuoka K, Nakazawa S, Ohtaki Y, Matsumura N, Yamazaki A, et al. SMARCB1‐Deficient Pulmonary Mesenchymal Tumor Without Malignant Histological Features. Pathology International. 2025. doi:10.1111/pin.70025

BibTeX
@article{Nakajima2025,
  author = {Nakajima, Nozomi and Fukuoka, Kohei and Nakazawa, Seshiru and Ohtaki, Yoichi and Matsumura, Nozomi and Yamazaki, Ayako and Yokoo, Hideaki and Yoshida, Akihiko and Nobusawa, Sumihito},
  title = {SMARCB1‐Deficient Pulmonary Mesenchymal Tumor Without Malignant Histological Features},
  journal = {Pathology International},
  year = {2025},
  doi = {10.1111/pin.70025}
}
Kostenlos starten →